NRx Pharmaceuticals (NASDAQ:NRXP) Receives Buy Rating from D. Boral Capital

NRx Pharmaceuticals (NASDAQ:NRXP)‘s stock had its “buy” rating reissued by D. Boral Capital in a research note issued to investors on Tuesday,Benzinga reports. They currently have a $34.00 price target on the stock.

A number of other equities research analysts have also issued reports on NRXP. Ascendiant Capital Markets lifted their target price on shares of NRx Pharmaceuticals from $48.00 to $49.00 and gave the company a “buy” rating in a research note on Monday, April 27th. Zacks Research raised shares of NRx Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Monday, March 2nd. BTIG Research reiterated a “buy” rating and set a $25.00 price objective on shares of NRx Pharmaceuticals in a report on Tuesday, March 24th. Finally, HC Wainwright reissued a “buy” rating and set a $45.00 price objective on shares of NRx Pharmaceuticals in a research report on Monday, April 27th. Four equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $38.25.

NRx Pharmaceuticals Stock Up 1.3%

Shares of NRXP traded up $0.04 during trading hours on Tuesday, reaching $3.04. The company’s stock had a trading volume of 1,329,956 shares, compared to its average volume of 1,062,989. The company has a 50 day moving average of $2.22 and a two-hundred day moving average of $2.32. The firm has a market cap of $100.53 million, a price-to-earnings ratio of -2.19 and a beta of 2.02. NRx Pharmaceuticals has a 1-year low of $1.62 and a 1-year high of $3.84.

NRx Pharmaceuticals (NASDAQ:NRXP) last posted its quarterly earnings results on Monday, March 23rd. The company reported $0.19 EPS for the quarter, topping the consensus estimate of ($0.09) by $0.28. The company had revenue of $0.98 million for the quarter, compared to analyst estimates of $7.53 million. As a group, analysts forecast that NRx Pharmaceuticals will post 0.13 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the business. Ethos Financial Group LLC raised its holdings in shares of NRx Pharmaceuticals by 33.6% during the 1st quarter. Ethos Financial Group LLC now owns 15,900 shares of the company’s stock valued at $34,000 after purchasing an additional 4,000 shares in the last quarter. One Wealth Management Investment & Advisory Services LLC boosted its holdings in NRx Pharmaceuticals by 35.3% in the fourth quarter. One Wealth Management Investment & Advisory Services LLC now owns 37,873 shares of the company’s stock worth $103,000 after purchasing an additional 9,882 shares in the last quarter. State Street Corp boosted its holdings in NRx Pharmaceuticals by 14.0% in the fourth quarter. State Street Corp now owns 86,984 shares of the company’s stock worth $236,000 after purchasing an additional 10,700 shares in the last quarter. Sjbenen Advisory LLC acquired a new position in NRx Pharmaceuticals during the fourth quarter worth $41,000. Finally, Two Sigma Investments LP increased its position in NRx Pharmaceuticals by 66.4% during the third quarter. Two Sigma Investments LP now owns 52,332 shares of the company’s stock worth $173,000 after buying an additional 20,880 shares during the last quarter. Institutional investors and hedge funds own 4.27% of the company’s stock.

About NRx Pharmaceuticals

NRx Pharmaceuticals, Inc is a clinical-stage specialty biopharmaceutical company focused on the development and repurposing of small-molecule therapeutics for central nervous system and rare disease indications. The company’s research strategy centers on advancing compounds with established safety profiles into new neurological and inflammatory conditions, leveraging translational science and biomarker-driven trial design to accelerate clinical development. NRx’s pipeline includes Ifenprodil, an NMDA receptor antagonist in investigation for acute respiratory distress syndrome and inflammatory muscle disorders, as well as investigational formulations targeting depressive and cognitive disorders.

Since securing global rights to its lead assets, NRx has initiated multiple proof-of-concept studies in the United States and Europe, collaborating with academic institutions and clinical research organizations to evaluate safety and efficacy across a range of indications.